Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types
- PMID: 3936634
- PMCID: PMC2536372
Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types
Abstract
A test was made of the susceptibility of 30 strains of Trypanosoma cruzi to chemotherapy with nifurtimox (Bay 2502) and benznidazole (Ro 7-1051). The strains had previously been classified as type I, II, or III according to their morphobiological and isoenzymic characteristics. Three type I strains, 14 type II strains, and 13 type III strains were studied. Mice were infected with 2 x 10(5) blood forms of these parasites and treated for 90 days with benznidazole or nifurtimox. All the surviving mice were submitted to parasitological tests (direct parasitaemia, xenodiagnosis, inoculation in new-born mice, and haemoculture) and serological tests (indirect immunofluorescence). As the latter remained positive in about 80% of the parasitologically negative animals, the cure rates were based on the more reliable parasitological tests. Type I strains displayed high susceptibility, type II strains showed medium to high susceptibility, and type III strains were highly resistant to both drugs. The fact that a particular strain type, with its own level of susceptibility, usually predominates in a given geographical area may explain the contradictory results after chemotherapy from different endemic areas.
Similar articles
-
[Therapy of the chronic phase of the experimental infection by Trypanosoma cruzi with benzonidazole and nifurtimox].Rev Soc Bras Med Trop. 1989 Jul-Sep;22(3):113-8. doi: 10.1590/s0037-86821989000300001. Rev Soc Bras Med Trop. 1989. PMID: 2518608 Portuguese.
-
Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.Trans R Soc Trop Med Hyg. 1987;81(5):755-9. doi: 10.1016/0035-9203(87)90020-4. Trans R Soc Trop Med Hyg. 1987. PMID: 3130683
-
[Treatment of Chagas' disease].Rev Med Chil. 1985 Feb;113(2):162-6. Rev Med Chil. 1985. PMID: 3936147 Clinical Trial. Spanish. No abstract available.
-
Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).Cochrane Database Syst Rev. 2020 Dec 11;12(12):CD004102. doi: 10.1002/14651858.CD004102.pub3. Cochrane Database Syst Rev. 2020. PMID: 33305846 Free PMC article.
-
[The chemotherapy of Chagas disease].Medicina (B Aires). 1999;59 Suppl 2:147-65. Medicina (B Aires). 1999. PMID: 10668258 Review. Spanish.
Cited by
-
Efficacy and mechanisms of alpha-solasonine-and alpha-solamargine-induced cytolysis on two strains of Trypanosoma cruzi.J Chem Ecol. 2006 Nov;32(11):2405-16. doi: 10.1007/s10886-006-9153-5. J Chem Ecol. 2006. PMID: 17001530
-
The repositioned drugs disulfiram/diethyldithiocarbamate combined to benznidazole: Searching for Chagas disease selective therapy, preventing toxicity and drug resistance.Front Cell Infect Microbiol. 2022 Jul 29;12:926699. doi: 10.3389/fcimb.2022.926699. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35967878 Free PMC article.
-
Trypanosoma cruzi I and IV stocks from Brazilian Amazon are divergent in terms of biological and medical properties in mice.PLoS Negl Trop Dis. 2013;7(2):e2069. doi: 10.1371/journal.pntd.0002069. Epub 2013 Feb 21. PLoS Negl Trop Dis. 2013. PMID: 23437410 Free PMC article.
-
Treatment of chronic experimental Trypanosoma cruzi infections in mice with MK-436, a 2-substituted 5-nitroimidazole.Bull World Health Organ. 1989;67(5):509-14. Bull World Health Organ. 1989. PMID: 2515007 Free PMC article.
-
Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome.PLoS Negl Trop Dis. 2011 Jun;5(6):e1216. doi: 10.1371/journal.pntd.0001216. Epub 2011 Jun 28. PLoS Negl Trop Dis. 2011. PMID: 21738811 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials